The stock of Climb Bio Inc. (CLYM) has seen a -7.65% decrease in the past week, with a -29.47% drop in the past month, and a -48.01% decrease in the past quarter. The volatility ratio for the week is 5.85%, and the volatility levels for the past 30 days are at 10.11% for CLYM. The simple moving average for the past 20 days is -8.72% for CLYM’s stock, with a -16.80% simple moving average for the past 200 days.
Is It Worth Investing in Climb Bio Inc. (NASDAQ: CLYM) Right Now?
The stock has a 36-month beta value of -0.39. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLYM is 51.90M, and at present, short sellers hold a 6.42% of that float. On October 23, 2024, the average trading volume of CLYM was 513.22K shares.
CLYM) stock’s latest price update
The stock of Climb Bio Inc. (NASDAQ: CLYM) has decreased by -1.76 when compared to last closing price of 4.71.Despite this, the company has seen a loss of -7.65% in its stock price over the last five trading days. globenewswire.com reported 2024-10-15 that Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trial s in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 12:00 p.m. ET Today WELLESLEY HILLS, Mass.
CLYM Trading at -25.80% from the 50-Day Moving Average
After a stumble in the market that brought CLYM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.94% of loss for the given period.
Volatility was left at 10.11%, however, over the last 30 days, the volatility rate increased by 5.85%, as shares sank -16.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.88% lower at present.
During the last 5 trading sessions, CLYM fell by -7.98%, which changed the moving average for the period of 200-days by +64.06% in comparison to the 20-day moving average, which settled at $5.07. In addition, Climb Bio Inc. saw 71.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLYM starting from Pimblett Emily, who sale 1,191 shares at the price of $8.18 back on Sep 20 ’24. After this action, Pimblett Emily now owns 7,564 shares of Climb Bio Inc., valued at $9,741 using the latest closing price.
Morisset Valerie, the EVP, R&D AND CSO of Climb Bio Inc., sale 69,005 shares at $8.03 during a trade that took place back on Jul 22 ’24, which means that Morisset Valerie is holding 31,317 shares at $554,170 based on the most recent closing price.
Stock Fundamentals for CLYM
Equity return is now at value -38.35, with -37.51 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 60.41.
Conclusion
To sum up, Climb Bio Inc. (CLYM) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
